Clinical

Dataset Information

0

Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).


ABSTRACT: Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals. Oral administration of Placebo 7.5g/day t.i.d. after meals. Primary outcome(s): Incidence of oral mucositis. grade>=2 Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619737 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-06-15 | E-GEOD-83349 | biostudies-arrayexpress
2016-06-15 | GSE83349 | GEO
2009-01-01 | GSE10746 | GEO
2016-12-19 | GSE81979 | GEO
2016-07-15 | E-GEOD-76003 | biostudies-arrayexpress
2009-01-14 | E-GEOD-10746 | biostudies-arrayexpress
| 2619732 | ecrin-mdr-crc
2014-10-16 | GSE62395 | GEO
| PRJEB49175 | ENA
2023-06-09 | PXD040398 | Pride